Table.
Potential link between antiviral mechanisms and antifibrotic drugs
| Inhibits viral infection or disease | Inhibits experimental acute lung injury | Inhibits IL-1 or IL-1 effects | Inhibits IL-6 | |
|---|---|---|---|---|
| Nintedanib | Not described | Not described | Yes38, 39 | Yes40, 41 |
| Pirfenidone | Not described | Yes42 | Yes43, 44 | Yes42 |
| αvβ6 integrin blockers and knockout mice | Yes45, 46 | Yes47, 48 | Yes48 | Yes49 |
| Gal-3 inhibitor and knockout mice | Yes50, 51 | Yes51, 52 | Yes51 | Not described |
| Autotaxin inhibitor | Not described | Not described | Not described | Yes (skin);53 not described |
| Lysophosphatidic acid inhibitor (BMS-986020; SAR100842) | No | Yes54 | Not described | Yes (skin)53 |
| JNK inhibitor | Yes55, 56, 57, 58 | Yes59 | Not described | Yes |
| mTOR pathway modulator | Yes60 | Yes61 | Yes61 | Yes43 |
| SAP (also known as PTX2) | Yes60, 62, 63 | Yes64 | Not described | Not described |
| AT2R inhibitor | Not described | Yes65, 66 | No44 | Yes65 |